NYSE Euronext Welcomes AbbVie to Its European and U.S. Markets



New York, Paris, January 2, 2013 – Today,AbbVie (ticker symbol: ABBV), a global research-based biopharmaceutical company formed in 2013 following separation from Abbott (ticker symbol: ABT), marked its cross-listing on NYSE Euronext (NYX) markets in Europe and the United States by ringing the Opening Bell in New York. AbbVie used the streamlined, cost-effective Fast Path process to cross-list in Europe, making it the fifteenth company to take advantage of this procedure since it was made available by NYSE Euronext in 2008.

AbbVie’s Common Stock was admitted to listing and trading on the NYSE Euronext markets by direct listing of its approximately 1.58 billion existing shares making up its capital and representing a market capitalization of €40 billion/ $54 billion.

Richard Gonzalez, CEO of AbbVie, said: “Today AbbVie launches with an outstanding portfolio, a solid pipeline and enthusiastic people who will serve patients and deliver growth. With those assets and a relentless focus on innovation we intend to create significant value for our shareholders.”

We welcome AbbVie to the community of NYSE Euronext listed companies and applaud its decision to cross-list on our European and U.S. markets which will reinforce its global identity”, added Scott Cutler, EVP, Head of Global Listings at NYSE Euronext. “This is the beginning of a lasting relationship that will give AbbVie the benefits of the highest levels of service, liquidity and transparency available through NYSE Euronext.”

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2024, Euronext N.V. - All rights reserved.